In 2007, our company developed Mucosal Immunity Inducing Protein (MIIP) from brewer’s yeast through specialized fermentation processes. Laboratory testing revealed that MIIP non-specifically attaches to bacterial cell membranes. Additionally, MIIP binds to the gut mucous membrane, releasing signals to immune cells that stimulate an immune response. Around the time, the swine industry was facing with severe challenges, Rotavirus and Porcine Reproductive and Respiratory Syndrome Virus (PRRSv). In response, we apply MIIP into swine feed to enhance breeding rates.
Since 2013, San Shin Nutrition Technology Inc. has collaborated with Dr. Chang from National Chiayi University to measure PRRSv ELISA antibody levels in swine fed with MIIP. Results showed improved breeding rate and antibody positive rate in swine given MIIP compared to those without. Following these findings, Mr. Yu conducted a simultaneous comparison test at Yan’s pig farm in Xiaying District, Tainan. This test indicated that swine fed with MIIP exhibited no PRRSv ELISA antibody response in their serum, suggesting they had not been infected, while the control group remained positive. This confirmed that MIIP could non-specifically bind to PRRSv and activate the immune system to produce IgA, protecting swine from viral infections.
Since MIIP could prevent PRRSv infections, it seemed possible to against rapidly mutating viruses like avian influenza (AI). In the winter of 2013, Mr. Yu tried to treat MIIP in chicken. When avian influenza broke out, MIIP protect chickens from infection, while the control group experienced the epidemic. Seven days later, AI ELISA antibody levels in the MIIP-fed chickens remained negative. Since 2015, MIIP has been applied on geese and laying hens, preventing avian influenza outbreaks.
In 2016, Mr. Yu collaborated with National Pingtung University of Science and Technology and National Defense University to evaluate the effects of through PRRSv challenge tests in swine and H1N1 challenge tests in mice. The results indicated that viral loads in the serum of the MIIP groups dropped significantly, compare with the control groups. Notably, the neutralizing antibody for PRRSv typically appears within four weeks after infection, yet the experimental group showed the presence of this antibody within one day of MIIP administration. The rapid response may attribute to MIIP activate the mucosal immunity, which generated the specific IgA antibody to eliminate the virus.
Following the unique efficacy of non-specifically binding to antigens and induced the mucosal immunity to product IgA antibody, we named it Mucosal Immunity Inducing Protein (MIIP).
Through these PRRSv and H1N1 challenge tests, MIIP has shown not only in preventing disease but also in treating. MIIP may be a possible way to develop as a new medicine.
San Shin Nutrition 